BioPorto enrolls first patient in U.S. Adult NGAL validation
BioPorto enrolled the first patient in its U.S. Adult Urine NGAL Validation Study for ProNephro AKI, targeting about 900 ICU patients across multiple sites to support a potential U.S. adult indication.
BioPorto A/S said it has enrolled the first patient in its U.S. Adult Urine NGAL Validation Study for ProNephro AKI. The company said the study is designed to include approximately 900 ICU patients across multiple sites to support a potential U.S. adult indication.